EN1001

**EN1001** is a proprietary TNFR1-binding protein developed by Enosi Life Sciences for the treatment of autoimmune diseases, acute inflammation, and potentially cancer. It selectively inhibits **Tumor Necrosis Factor Receptor 1 (TNFR1)**, the primary mediator of TNF-driven pro-inflammatory signaling, without affecting the anti-inflammatory **TNFR2**, addressing limitations of existing TNF blockers that co-inhibit both receptors and lead to reduced efficacy or safety issues. Unlike broad TNF inhibitors, EN1001 targets the root of TNF-mediated pathology more precisely, with potential applications in rheumatoid arthritis, cytokine storms (e.g., COVID-19), endometriosis, and Alzheimer's disease.[1][2][6]